Hims & Hers Stock Surges 14% as FDA Plans Review of Peptide Compounding Eligibility

The FDA's upcoming panel meeting in July to evaluate seven peptides for compounding has sparked a 14% increase in Hims & Hers stock, reflecting investor optimism about potential market expansion. The review could open new growth opportunities for the company in peptide-based therapies. Monitoring the panel's decision will be crucial, as its ruling may significantly influence Hims & Hers' entry into this segment.